Ceftolozane/tazobactam – the "new player" in a battle against multiresistant pathogens
Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper we reviewed the data on antimicrobial activity, ph...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy
2018-11-01
|
| Series: | Клиническая микробиология и антимикробная химиотерапия |
| Subjects: | |
| Online Access: | https://cmac-journal.ru/publication/2018/4/cmac-2018-t20-n4-p354/cmac-2018-t20-n4-p354.pdf |
| Summary: | Ceftolozane/tazobactam is a new combined antibacterial agent for the treatment of infections caused by gram-negative microorganisms, P. aeruginosa in particular, including strains resistant to other clinically available antimicrobials. In this paper we reviewed the data on antimicrobial activity, pharmacokinetics, clinical efficacy and safety of ceftolozane/tazobactam, as well as its potential role for the treatment of complicated intra-abdominal infections and urinary tract infections. |
|---|---|
| ISSN: | 1684-4386 2686-9586 |